MSN 571 PHARMACOLOGY FINAL EXAM

MSN 571 PHARMACOLOGY FINAL EXAM 1) A 40-year old female patient is being followed up for diabetes mellitus. She is currently onMetformin 1 gram twice a day and has been tolerating it well for about six months. Her hemoglobin A1c a week ago was 8.9%. The plan is to initiate liraglutide therapy in addition to the metformin. Which of the following statements is true with regards to liraglutide.  Liraglutide may be stored in the refrigerator or freezer prior to first use.  The brand name is Bydureon  Nausea and/or vomiting are common side effects of therapy  It should be administered intramuscularly into the upper arm. 2) The patient who takes insulin has just been prescribed a beta blocker drug. You recognize thatthe interaction of the beta blocker and the insulin may have which result?  Decreased activity of the beta blocker drug  Enhanced activity of the beta blocker drug  Masked signs of hypoglycemia  Masked signs of hyperglycemia 3) Which classification of oral hypoglycemic drugs decreases hepatic glucose production andincreases insulin sensitivity and peripheral glucose uptake?  Sulfonylureas (glyburide)  Meglitinides (glinides)  Biguanide (metformin)  alpha-glycosidase inhibitor (miglitol)